Claims
- 1. An isolated nucleic acid molecule nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding the Ependymin polypeptide having the complete amino acid sequence in SEQ ID NO:2 (i.e., positions −37 to 187 of SEQ ID NO:2); (b) a nucleotide sequence encoding the Ependymin polypeptide having the complete amino acid sequence in SEQ ID NO:2 excepting the N-terminal methionine (i.e., positions −36 to 187 of SEQ ID NO:2); (c) a nucleotide sequence encoding the predicted mature Ependymin polypeptide having the amino acid sequence at positions 1 to 187 in SEQ ID NO:2; (d) a nucleotide sequence encoding the Ependymin polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464; (e) a nucleotide sequence encoding the Ependymin polypeptide having the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 209464; (f) a nucleotide sequence encoding the mature Ependymin polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464; and (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e) or (f), above.
- 2. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence in FIGS. 1A, 1B, and 1C (SEQ ID NO:1).
- 3. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 1A, 1B, and 1C (SEQ ID NO:1) encoding the Ependymin polypeptide having the amino acid sequence in positions −37 to 187 of SEQ ID NO:2.
- 4. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 1A, 1B, and 1C (SEQ ID NO:1) encoding the mature Ependymin polypeptide having the amino acid sequence from about 1 to about 187 in SEQ ID NO:2.
- 5. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of residues n-187 of SEQ ID NO:2, where n is an integer in the range of −37 to 5; (b) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of residues −37-m of SEQ ID NO:2, where m is an integer in the range of 173 to 187; (c) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues n-m of SEQ ID NO:2, where n and m are integers as defined respectively in (a) and (b) above; and (d) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Ependymin amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464 wherein said portion excludes from 1 to about 42 amino acids from the amino terminus of said complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464; (e) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Ependymin amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464 wherein said portion excludes from 1 to about 15 amino acids from the carboxy terminus of said complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464; and (f) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Ependymin amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464 wherein said portion include a combination of any of the amino terminal and carboxy terminal deletions in (d) and (e), above.
- 6. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone contained in ATCC Deposit No. 209464.
- 7. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the Ependymin polypeptide having the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 209464.
- 8. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the mature Ependymin polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209464.
- 9. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), (f) or (g) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
- 10. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a Ependymin polypeptide having an amino acid sequence in (a), (b), (c), (d), (e) or (f) of claim 1.
- 11. The isolated nucleic acid molecule of claim 10, which encodes an epitope-bearing portion of a Ependymin polypeptide wherein the amino acid sequence of said portion is selected from the group of sequences in SEQ ID NO:2 consisting of: about Ala-1 to about Gln-9; about Pro-8 to about Val-16; about Gln-19 to about Arg-27; about Ile-69 to about Ser-77; about Asp-86 to about Glu-107; about Glu-113 to about Tyr-123; about Thr-131 to about Gln-139; about Leu-159 to about Phe-167; and about Leu-178 to about Ser-186.
- 12. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.
- 13. A recombinant vector produced by the method of claim 12.
- 14. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 13 into a host cell.
- 15. A recombinant host cell produced by the method of claim 14.
- 16. A recombinant method for producing a Ependymin polypeptide, comprising culturing the recombinant host cell of claim 15 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 17. An isolated Ependymin polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
(a) the amino acid sequence of the full-length Ependymin polypeptide having the complete amino acid sequence shown in SEQ ID NO:2 (i.e., positions −37 to 187 of SEQ ID NO:2); (b) the amino acid sequence of the full-length Ependymin polypeptide having the complete amino acid sequence shown in SEQ ID NO:2 excepting the N-terminal methionine (i.e., positions −36 to 187 of SEQ ID NO:2); (c) the amino acid sequence of the predicted mature Ependymin polypeptide having the amino acid sequence at positions 1 to 187 in SEQ ID NO:2; (d) the complete amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit No. 209464; (e) the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in the ATCC Deposit No. 209464; and (f) the complete amino acid sequence of the predicted mature Ependymin polypeptide encoded by the cDNA clone contained in the ATCC Deposit No. 209464.
- 18. An isolated polypeptide comprising an epitope-bearing portion of the Ependymin protein, wherein said portion is selected from the group consisting of: a polypeptide comprising amino acid residues from about Ala-1 to about Gln-9 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about Pro-S to about Val-16 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about Gln-19 to about Arg-27 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about Ile-69 to about Ser-77 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about Asp-86 to about Glu-107 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about Glu-113 to about Tyr-123 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about Thr-131 to about Gln-139 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about Leu-159 to about Phe-167 in SEQ ID NO:2; and a polypeptide comprising amino acid residues from about Leu-178 to about Ser-186 in SEQ ID NO:2.
- 19. An isolated antibody that binds specifically to a Ependymin polypeptide of claim 17.
- 20. An isolated polynucleotide encoding a modified Ependymin protein, wherein, except for at least one conservative amino acid substitution, said modified peptide has an amino acid sequence that is identical to a member selected from the group consisting of:
(a) amino acids −37 to 187 of SEQ ID NO:2; (b) amino acids −36 to 187 of SEQ ID NO:2; and (c) amino acids 1 to 187 of SEQ ID NO:2.
- 21. A modified Ependymin, wherein, except for at least one conservative amino acid substitution, said modified peptide has an amino acid sequence that is identical to a member selected from the group consisting of:
(a) amino acids −37 to 187 of SEQ ID NO:2; (b) amino acids −36 to 187 of SEQ ID NO:2; and (c) amino acids 1 to 187 of SEQ ID NO:2.
- 22. An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:15; (b) the nucleotide sequence of SEQ ID NO:16; (c) the nucleotide sequence of SEQ ID NO:17; (d) the nucleotide sequence of SEQ ID NO:18; (e) the nucleotide sequence of SEQ ID NO:19; (f) the nucleotide sequence of SEQ ID NO:20; (g) the nucleotide sequence of a portion of the sequence shown in FIGS. 1A, 1B, and 1C (SEQ ID NO:1) wherein said portion comprises at least 50 contiguous nucleotides from nucleotide 1 to nucleotide 2505; and (h) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f) or (g), above.
- 23. A method for the treatment of a patient having need of human ependymin polypeptide comprising:
(a) isolating the polypeptide of claim 1, and (b) administering to the patient a therapeutically effective amount of said polypeptide.
- 24. A method for identifying compounds which bind to and inhibit activation of the polypeptide of claim 1 comprising:
(a) contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with an analytically detectable human cytokine polypeptide and a compound under conditions to permit binding to the receptor; and (b) determining whether the compound binds to and inhibits the receptor by detecting the absence of a signal generated from the interaction of the human ependymin polypeptide with the receptor.
- 25. A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 1 comprising:
(a) isolating a sample of the nucleic acid sequence encoding said polypeptide, and (b) determining a mutation in a nucleic acid sequence encoding said polypeptide.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser. No. 10/187,904, filed Jul. 3, 2002, which is a divisional of U.S. application Ser. No. 09/229,583, filed Jan. 13, 1999, (now U.S. Pat. No. 6,489,138, issued Dec. 3, 2002), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/071,330, filed on Jan. 14, 1998, and 60/075,278, filed on Feb. 19, 1998, each of which is hereby incorporated by reference in its entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60071330 |
Jan 1998 |
US |
|
60075278 |
Feb 1998 |
US |
Divisions (2)
|
Number |
Date |
Country |
Parent |
10187904 |
Jul 2002 |
US |
Child |
10733646 |
Dec 2003 |
US |
Parent |
09229583 |
Jan 1999 |
US |
Child |
10187904 |
Jul 2002 |
US |